PL2475352T5 - Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji - Google Patents
Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacjiInfo
- Publication number
- PL2475352T5 PL2475352T5 PL09741462T PL09741462T PL2475352T5 PL 2475352 T5 PL2475352 T5 PL 2475352T5 PL 09741462 T PL09741462 T PL 09741462T PL 09741462 T PL09741462 T PL 09741462T PL 2475352 T5 PL2475352 T5 PL 2475352T5
- Authority
- PL
- Poland
- Prior art keywords
- ethanolamide
- composition containing
- containing ultra
- palmitoyl
- micronized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09741462.7A EP2475352B2 (en) | 2009-09-07 | 2009-09-07 | Composition containing ultra-micronized palmitoyl - ethanolamide |
PCT/IT2009/000399 WO2011027373A1 (en) | 2009-09-07 | 2009-09-07 | Composition containing ultra-micronized palmitoyl - ethanolamide |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2475352T3 PL2475352T3 (pl) | 2016-01-29 |
PL2475352T5 true PL2475352T5 (pl) | 2019-02-28 |
Family
ID=42211652
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09741462T PL2475352T5 (pl) | 2009-09-07 | 2009-09-07 | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
PL14157421T PL2796129T3 (pl) | 2009-09-07 | 2009-09-07 | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14157421T PL2796129T3 (pl) | 2009-09-07 | 2009-09-07 | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
Country Status (14)
Country | Link |
---|---|
US (2) | US8470373B2 (pl) |
EP (2) | EP2796129B1 (pl) |
JP (1) | JP5746178B2 (pl) |
KR (1) | KR101662871B1 (pl) |
CN (2) | CN102186459A (pl) |
AR (2) | AR078159A1 (pl) |
AU (1) | AU2009352080B2 (pl) |
BR (1) | BRPI0919753B8 (pl) |
CA (1) | CA2738117C (pl) |
CY (2) | CY1116695T1 (pl) |
ES (2) | ES2547133T5 (pl) |
PL (2) | PL2475352T5 (pl) |
PT (2) | PT2796129E (pl) |
WO (1) | WO2011027373A1 (pl) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2262763A2 (en) | 2008-03-04 | 2010-12-22 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Compounds and methods of treating obesity |
JP5746178B2 (ja) | 2009-09-07 | 2015-07-08 | エピテック・グループ・エス.アール.エル. | 超微粉化パルミトイル−エタノールアミドを含む組成物 |
WO2014013497A1 (en) * | 2012-07-20 | 2014-01-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Fatty acid derivatives for use in a method of treating depression and associated conditions |
ITMI20130354A1 (it) | 2013-03-08 | 2014-09-09 | Again Life Italia Srl | Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie. |
ES2603809T3 (es) | 2014-03-19 | 2017-03-01 | Epitech Group S.R.L. | Composición farmacéutica que comprende palmitoiletanolamida y L-acetilcarnitina |
EP2921171B1 (en) * | 2014-03-21 | 2019-10-16 | EPITECH GROUP S.p.A. | Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines |
PL2944309T3 (pl) * | 2014-05-14 | 2019-09-30 | Epitech Group S.P.A. | Zastosowanie palmitoiloetanoloamidu w połączeniu z opioidami |
EP2965765B1 (en) | 2014-07-08 | 2019-05-08 | EPITECH GROUP S.p.A. | Use of adelmidrol in the treatment of epithelial dysfunctions |
ES2641143T3 (es) | 2014-08-13 | 2017-11-07 | Epitech Group S.P.A. | Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina |
JP2015155412A (ja) * | 2015-03-03 | 2015-08-27 | エピテック・グループ・エス.アール.エル. | 超微粉化パルミトイル−エタノールアミドを含む組成物 |
NL2014464B1 (en) * | 2015-03-16 | 2017-01-13 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain. |
AU2016254685B2 (en) * | 2015-04-29 | 2021-04-22 | Scisparc Ltd | Combinations of cannabinoids and N-acylethanolamines |
WO2016183134A1 (en) * | 2015-05-12 | 2016-11-17 | Cutting Edge Medical Solutions, Llc | Palmitoylethanolamide compositions |
CN116999410A (zh) | 2015-08-11 | 2023-11-07 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
ITUB20153066A1 (it) | 2015-08-11 | 2017-02-11 | Graal S R L | Composizione alimentare e/o nutraceutica contenente pea |
ITUB20154849A1 (it) * | 2015-10-30 | 2017-04-30 | Epitech Group S P A | ADELMIDROL PER L'USO NELLE PATOLOGIE CARATTERIZZATE DA INSUFFICIENTE AGONISMO DEL RECETTORE PPAR-gamma |
ES2580508B1 (es) * | 2016-04-11 | 2018-09-12 | Servicio Andaluz De Salud | Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol. |
NL2017559B1 (en) * | 2016-09-30 | 2018-04-10 | Vanderbilt Science Holding Ltd | Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles |
CN106478445A (zh) * | 2016-11-07 | 2017-03-08 | 华中药业股份有限公司 | 一种非那西丁微粉的制备方法 |
EP3417846A1 (en) | 2017-06-19 | 2018-12-26 | Gifar Srl | Food and/or nutraceutical composition |
IT201700068608A1 (it) * | 2017-06-20 | 2018-12-20 | Neilos S R L | Composizione per trattamento o prevenzione di una malattia neurodegenerativa |
MY172113A (en) * | 2017-07-05 | 2019-11-14 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
MY186286A (en) | 2017-09-05 | 2021-07-05 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
IT201800003912A1 (it) * | 2018-03-26 | 2019-09-26 | Innovet Italia Srl | N-palmitoil-d-glucosamina in forma micronizzata |
IT201800004439A1 (it) * | 2018-04-12 | 2019-10-12 | ASSOCIAZIONE DI CURCUMA (Curcuma longa L.), PALMITOILETANOLAMIDE (PEA) E L-TRIPTOFANO | |
WO2021048871A1 (en) * | 2019-09-15 | 2021-03-18 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for treating neurological disorders |
EP3838346A1 (en) * | 2019-12-20 | 2021-06-23 | Chemo Research SL | Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid |
US11684600B2 (en) * | 2020-03-04 | 2023-06-27 | Compact Disc Incorporated | Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort |
IT202000007831A1 (it) | 2020-04-14 | 2021-10-14 | Epitech Group S P A | Adelmidrol per l’uso nel trattamento della fibrosi polmonare |
GR20200100479A (el) * | 2020-08-13 | 2022-03-09 | Pharma Unimedis Ike, | Συμπληρωμα διατροφης για την προληψη και/ή τη θεραπεια του πονου και/ή νευροπαθειων |
WO2022141821A1 (zh) * | 2020-12-29 | 2022-07-07 | 汉义生物科技(北京)有限公司 | 一种***素泡腾制剂及其制备方法 |
IT202100006494A1 (it) * | 2021-03-18 | 2022-09-18 | Epitech Group S P A | N-palmitoil-etanolamide per l’uso nella prevenzione del carcinoma colo-rettale |
IT202100015278A1 (it) | 2021-06-11 | 2022-12-11 | Epitech Group S P A | Composizione di n-palmitoil-etanolamide e baicaleina in forma comicronizzata |
IT202100024464A1 (it) * | 2021-09-23 | 2023-03-23 | Epitech Group S P A | N-palmitoil-etanolamide e acido docosaesaenoico per l’uso nel trattamento del disturbo dello spettro autistico e di altre sindromi depressive |
WO2023133555A2 (en) * | 2022-01-10 | 2023-07-13 | Zilker Sciences Llc | Palmitoylethanolamide treatment for covid-19-related inflammation |
EP4289421A1 (en) * | 2022-06-07 | 2023-12-13 | Erbozeta S.p.A. | Combination of palmitoylethanolamide (pea) and melatonin for the treatment of mast cell hyper-reactivity |
EP4331577A1 (en) * | 2022-08-30 | 2024-03-06 | Unifarco S.p.A. | A nutraceutic tablet comprising palmitoylethanolamide |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
AU3564589A (en) | 1988-05-17 | 1989-12-12 | Liposome Technology, Inc. | Preparation of uniform-size liposomes and other lipid structures |
IT1252865B (it) * | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni |
US5679667A (en) | 1992-04-24 | 1997-10-21 | Lifegroup S.P.A. | Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve |
WO1994028876A1 (en) | 1993-06-07 | 1994-12-22 | Advanced Therapies, Inc. | Liposome powders |
US5622715A (en) | 1994-06-10 | 1997-04-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of improving renal function |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
IT1271266B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
US5874029A (en) | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
IT1302264B1 (it) | 1998-09-24 | 2000-09-05 | Innovet Italia Srl | Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi |
EP1207870B1 (en) | 1999-08-06 | 2005-03-16 | Innovet Italia S.r.l. | Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
JPWO2006077824A1 (ja) | 2005-01-18 | 2008-08-07 | 国立大学法人京都大学 | 神経細胞再生のための医薬 |
EP1844784B1 (en) * | 2006-03-28 | 2010-04-21 | Epitech Group S.r.l. | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system |
NZ552290A (en) | 2006-12-21 | 2009-05-31 | Bomac Research Ltd | Tablet fomulation |
JP5746178B2 (ja) | 2009-09-07 | 2015-07-08 | エピテック・グループ・エス.アール.エル. | 超微粉化パルミトイル−エタノールアミドを含む組成物 |
-
2009
- 2009-09-07 JP JP2012527452A patent/JP5746178B2/ja active Active
- 2009-09-07 ES ES09741462T patent/ES2547133T5/es active Active
- 2009-09-07 ES ES14157421.0T patent/ES2548190T3/es active Active
- 2009-09-07 CN CN2009801409003A patent/CN102186459A/zh active Pending
- 2009-09-07 US US13/120,408 patent/US8470373B2/en active Active
- 2009-09-07 PT PT141574210T patent/PT2796129E/pt unknown
- 2009-09-07 EP EP14157421.0A patent/EP2796129B1/en active Active
- 2009-09-07 EP EP09741462.7A patent/EP2475352B2/en active Active
- 2009-09-07 PT PT97414627T patent/PT2475352E/pt unknown
- 2009-09-07 PL PL09741462T patent/PL2475352T5/pl unknown
- 2009-09-07 CN CN201610542680.9A patent/CN106138022A/zh active Pending
- 2009-09-07 PL PL14157421T patent/PL2796129T3/pl unknown
- 2009-09-07 AU AU2009352080A patent/AU2009352080B2/en active Active
- 2009-09-07 WO PCT/IT2009/000399 patent/WO2011027373A1/en active Application Filing
- 2009-09-07 BR BRPI0919753A patent/BRPI0919753B8/pt active IP Right Grant
- 2009-09-07 CA CA2738117A patent/CA2738117C/en active Active
- 2009-09-07 KR KR1020127008978A patent/KR101662871B1/ko active IP Right Grant
-
2010
- 2010-09-06 AR ARP100103257A patent/AR078159A1/es not_active Application Discontinuation
-
2013
- 2013-06-24 US US13/925,435 patent/US8663701B2/en active Active
-
2015
- 2015-09-16 CY CY20151100814T patent/CY1116695T1/el unknown
- 2015-09-16 CY CY20151100815T patent/CY1116698T1/el unknown
-
2019
- 2019-08-09 AR ARP190102266A patent/AR115939A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2475352T5 (pl) | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji | |
GB0908129D0 (en) | Composition | |
GB0918450D0 (en) | Composition | |
GB0905863D0 (en) | Novel composition | |
ZA201107839B (en) | Composition | |
EP2409997A4 (en) | REDOX-HARDENING COMPOSITION | |
GB0911428D0 (en) | Composition | |
ZA201107838B (en) | Composition | |
GB0909362D0 (en) | Composition | |
GB0908642D0 (en) | Composition | |
HK1164356A1 (en) | Composition | |
IL216395A0 (en) | Prothrombic complex composition | |
HK1169306A1 (en) | Composition having lipolysis-promoting effect | |
EP2394634A4 (en) | HESPERIDO-CONTAINING COMPOSITION | |
GB0906779D0 (en) | Composition | |
GB0922389D0 (en) | composition | |
GB0904941D0 (en) | Composition | |
EP2444061A4 (en) | COMPOSITION CONTAINING APIGENIN | |
GB0911294D0 (en) | Composition | |
GB0904942D0 (en) | Composition | |
GB201006350D0 (en) | Composition | |
GB0918590D0 (en) | Composition | |
GB0903688D0 (en) | Composition | |
GB0922133D0 (en) | Composition | |
GB0902959D0 (en) | Composition |